12 October 2020
Visiongain has published a new report on Pulmonary/Respiratory Drug Delivery Market Report 2020-2030: Forecasts by Product (Formulation, Devices), Formulation (Suspension Aerosol, Solution Aerosol, Dry Powder Formulation), Devices (MDIs, DPIs, Nebulizers, Accessories), Nebulizers (Soft Mist Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers), Canister Type (Plain Canisters, Coated Canister), Application (Asthma, COPD, Cystic Fibrosis, Other Applications), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, E-Commerce), End-user (Hospitals & Clinics, Homecare Settings), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) PLUS Profiles of Leading Respiratory Drug Delivery Companies PLUS COVID-19 Recovery Scenarios.
The global pulmonary/respiratory drug delivery market size was valued at US$ xx million in 2019 and is anticipated to reach US$ xx million in 2025 while growing at a CAGR of xx% during the first half of the forecast period i.e. 2020 to 2025. The global market size is further projected to reach US$ xx million by 2030 at a CAGR of xx% from 2025 to 2030. The overall CAGR for the global respiratory drug delivery market is expected to be xx% from 2020 to 2030.
COVID-19 Impact on Respiratory Drug Delivery Market
The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit. The developed markets themselves will see their revenues change, with Japan experiencing healthy growth. One restraint for the companies that operate in the more developed markets will be that the respiratory drug delivery market there is already quite mature. This means that there is greater competition amongst companies that operate in the respiratory drug delivery market. This will impact the ability of the companies to sell in these developed markets and gain a larger amount of revenue and market share.
Increase in Prevalence and Incidence of Respiratory Diseases
Prevalence and incidence of respiratory diseases are increasing worldwide because of various factors like noise, unhealthy lifestyle, and tobacco smoking. Approximately 65 million people, according to the WHO, have mild to extreme chronic obstructive pulmonary disease (COPD), around 3 million of whom die each year making it the world's third leading cause of death–and increasing numbers. About 334 million people worldwide are suffering from asthma, childhood's most prevalent chronic disease, affecting 14 percent of children. The prevalence of asthma is increasing among infants. Acute, lower respiratory tract infections have been among the top 3 causes of death & disability in adults and children for decades.
While the incidence is hard to quantify, lower respiratory tract infection is projected to cause approximately 4 million deaths each year and is a leading cause of death for children under the age of 5. In comparison, chronic respiratory diseases predispose children into later life with acute infections of the lower respiratory tract. Infections of the respiratory tract caused by influenza destroy between 250,000 and 500,000 individuals, and cost between $71 and $167 billion per year. As a result, increased prevalence and incidence of respiratory diseases are expected to drive demand for respiratory drug delivery devices including inhalers, MDIs, and nebulizers.
Trends in MDI Technology
There has been a lot of attention to the differences in the effects of numerous medications on Enantiomer, & a lot of consideration has been given to beta-agonist adrenergic bronchodilators. Recently, the active enantiomer of salbutamol levo salbutamol is present in the market, free of termers and palpitation saw in salbutamol. Spacers are used to enhance patient coordination with MDI. The Autohaler is the first dose metered inhaler to be actuated by breath or activated by pressure. Autohaler solves the key problem of the pMDIs and doesn’t rely on the patient's inspiratory effort to aerosolize the dry powder inhaler dose. The newer pMDIs can be categorized as coordination devices or breath-actuated. Breath-actuated pMDIs, such as the Easibreathe®, is a device that is designed to overcome the problem of poor coordination between the patient’s breath and inhaler actuation. The Easibreathe® device works according to the patient’s breath rate and automatically adjusts the trigger sensitivity for the activation of the device. The pMDIs are breath coordinated, devised to synchronize the inspiration rate along with the discharge of the dose from the inhaler.
Some of the companies profiled in the report include GlaxoSmithKline plc, Respironics, Inc., Boehringer Ingelheim, 3M, AstraZeneca, Merck & Co., Inc., Novartis AG, OMRON Corporation, Sunovion Pharmaceuticals Inc., Teva Pharmaceutical, F. Hoffmann-La Roche Ltd., Cipla, Pulmatrix, Respiratorius AB, Regeneron Pharmaceuticals, Inc., and Grifols, S.A. On 20th January 2020; Pulmatrix, Inc. announced that it has entered into a research collaboration with Nocion Therapeutics to explore new technologies to enable and improve inhaled drug delivery. The collaboration will leverage Pulmatrix's iSPERSE™ platform and expertise in seeking to transform promising assets to improve drug delivery and safety profiles.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.
19 April 2021
The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.
12 April 2021
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
09 April 2021
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.